Reasons why I see the reward being much greater than the risk here:
* They have a food intolerance test that sells & ships worldwide.
* They have been rapidly expanding the fingerstick allergy test nationwide through immunotherapy & marketing partnerships (marketing partners have mentioned that demand is high for this test). They also also seeking global expansion.
Note: About 60 million people suffer from allergies in the United States.
* They submitted a major product line to the FDA and is pending approval.
* They have confidential contracts with the FDA.
* They have a contract with the USDA.
* The “Arrayit Blood Card” has been utilized recently in a verified NIH clinical trial link & has been depicted in a very prestigious university research.
* They recently updated their website.
* They hired a new consultant this year.
* They hired an intern a couple months ago who “Compiled patients’ confidential demographic information alongside relevant lab data for analysis.”
News 
Market Data 
Discover 
